March 25, 2020
Nippon Chemiphar will obtain exclusive rights in Japan to commercialize and manufacture Tokushima-based biotech Delta-Fly Pharma’s investigational tumor microenvironment therapy DFP-17729, the two companies said on March 24. When tumor cells multiply, they release acidic substances out of the cells...read more